Trial Profile
A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Metformin/sitagliptin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 03 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 03 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.